Free Newsletter
FDA holds back on J&J schizophrenia drug
Johnson & Johnson will have to provide the FDA with more information about its candidate schizophrenia drug paliperidone palmitate before it gets approval, the company announced yesterday. J&J's Janssen will market the drug. While J&J did not disclose the specifics of the FDA request, the company did say it will not have to perform any additional studies on the drug and that it intends to comply with FDA and provide the requested information. Release
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: